THIS PAGE HAS BEEN ARCHIVED AND IS NO LONGER UPDATED.
We apologize for the inconvenience.
To find similar material or the current version of the page, please visit one the following resources:
Health Topics || Country Sites || News Releases || Our New Homepage


ESTA PÁGINA HA SIDO ARCHIVADA Y YA NO ES ACTUALIZADA.
Pedimos disculpas por la molestia.
Para encontrar material similar o una versión actualizada de la página, visite uno de los siguientes recursos:
Temas de salud || Sitios de países || Comunicados de prensa || Nuestra nueva página de inicio


Greivin Hernández-González, Max Valverde: Evaluación del impacto de las disposiciones de ADPIC+ en el mercado institucional de medicamentos de Costa Rica ["Assessment of the impact of TRIPS-Plus provisions on Costa Rica's institutional drug market"]. CINPE, ICTSD, PAHO/WHO, UNDP: Costa Rica, December 2009. 

The present study concludes that the "TRIPS-Plus" standards have certain economic effects including increased prices and thus increased public spending to purchase drugs, and also reduced competition in the generic drug industry. Analysis of the impact of "TRIPS-Plus" standards in Costa Rica is specific to the country since the national Constitution mandates the rights to health, access to medicines and social security. These guaranteed rights have been internalized in a practical way through the universal health service, which is inclusive and protective of consumers' rights. In this regard, the impact assessment in Costa Rica is focused exclusively on the institutional drug market.

pdf  Assessment of impact of the TRIPS provisions (2.25 MB)  (Spanish)